Lumexa Imaging Holdings, Inc. (LMRI) Earnings Call Transcript
March 26, 2026
Earnings Call Speaker Segments
Thanks so much, and welcome, everyone — we're glad you could be with us this morning. Our Chief Executive Officer, Caitlin Zulla, and our Chief Financial Officer, Tony Martin, are heading up today's call. I'd like to mention before we get started that we'll be talking about non-GAAP financial measures, which we believe are useful when assessing how Lumexa Imaging is performing. Information about how those measures connect to our GAAP figures, plus reconciliations, appears in the press release posted on our website. In addition, we'll be sharing forward-looking statements that reflect our present expectations and assumptions; these carry risks and uncertainties, among them the factors described in our press release and in the various filings we make with the SEC. Results in reality may differ materially, and we take on no duty to revise these forward-looking statements. So, I'll hand things over now to Caitlin. Caitlin, the floor is yours.
Thanks, Sue. Good morning, everyone, and I appreciate all of you being with us today for our first earnings call since becoming a public company. For Lumexa Imaging, the fourth quarter of 2025 represented a solid finish to a significant year, and we posted steady, consistent expansion in revenue and EBITDA that comes in above our preliminary earnings announcement. Consolidated revenue came to $267.7 million, which is 7.9% higher than Q4 of last year. Adjusted EBITDA reached $63.8 million, an 18.6% gain versus Q4 of last year, and produced a 23.8% adjusted EBITDA margin. Across the system, we performed 1.4 million advanced imaging exams during the quarter, a rise of 7.7% year-over-year. Several meaningful accomplishments defined 2025 for Lumexa Imaging. A few of the highlights are as follows: we pushed forward with our growth plans, setting a record for de novo openings and generating robust same-center growth. We rolled out a successful rebrand, introducing our new name, Lumexa Imaging, to better reflect our shared purpose, our innovative spirit and our dedication to expanding access and delivering exceptional care to additional patients and communities. We finished our IPO, raising greater awareness of our company among the investment community, widening access to our value creation opportunity and, by applying proceeds toward reducing our leverage profile, unlocking more cash to back our plans for profitable growth. Let me take a moment to consider the fundamentals of our business and why I believe a strong runway for continued growth lies ahead. Our clear value proposition keeps resonating with patients, providers and payers, as shown by our high patient Net Promoter Scores, which remain consistently above 90; we deliver enhanced access to high-quality imaging that helps patients move through treatment in more convenient settings and at meaningfully lower cost than hospital outpatient department or HOPD sites of care; we gain from multiple long-term demand tailwinds, among them aging populations with complex and chronic conditions, new treatment paradigms that call for advanced imaging, rising rates of preventative screening and a continuing migration from hospital and inpatient settings to outpatient imaging within a fragmented and capacity-constrained industry landscape. Our commercial efforts target higher growth and higher reimbursing advanced imaging modalities, such as MRI, CT and PET scans. We additionally provide routine modalities like X-ray and ultrasound, which are strategic and establish us as a convenient and comprehensive solution for patients, even though those modalities serve as a less meaningful driver of our financial results; we are implementing a focused and disciplined profitable growth algorithm rooted in same-center growth, geographic expansion, strategic service line expansion and delivering efficiencies throughout our company, including select AI-enabled solutions. And by leveraging technology, encompassing our existing tech stack along with innovations being developed in coming months and years, we are well positioned to drive better outcomes and efficiencies. As we look ahead to 2026, our confidence stems from solid performance and the belief that here at Lumexa Imaging, we're still in the early stages of seizing the opportunities in front of us; our mission inspires us—broadening access to top-tier imaging via enhanced, compassionate care, bettering lives and pushing health care forward nationwide. Now, let me take a moment to go over the main strategic efforts we're targeting for 2026. To start, our top strategic priority is generating growth within existing centers. Keep in mind that roughly 2/3 of our revenue growth typically comes from higher procedure volume, while the other 1/3 comes from rates, pushed by gains in both rate per unit and acuity mix, or the share of advanced modalities. Our commercial team is intensely focused on fueling same-center growth. To illustrate, I'll offer a few examples from Q4. In Orthopedic, we rolled out a focused marketing and sales outreach push, generating added growth from a top referring specialty provider segment during their busiest surgical period. Mammography is another area where our teams are building momentum. About 85% of our screening volume originates from current patients returning for their yearly exam, which shows strong patient trust and retention. By using our CRM tools and scheduling proactively during patient visits, we significantly boosted our annual screening compliance rate. We also kicked off marketing campaigns to fuel a solid rise in new mammography patients during 2025. When yearly compliance rates climb, breast cancer is found and treated earlier more often, which saves lives and reduces health care costs. While we generate greater demand at our current centers, we're also working to operate more efficiently to handle this rising outpatient imaging volume. Here are some examples. Thanks to AI-powered faster scanning technology, we lifted schedule throughput by almost 40% and enhanced image clarity from when it was introduced. By the close of 2025, our FastScan integration and rollout had reached roughly 50% completion across all our centers, and we anticipate hitting about 2/3 adoption by the close of 2026. Virtual cockpit for remote MRI scanning is another innovation we're bringing in. This tech lets us reduce the effects of machine downtime, adjust our staffing schedules flexibly and expand hours to serve patients. Our next strategic priority for 2026 centers on geographic expansion. We intend to accomplish this via new de novo launches, JV partnerships and handpicked M&A. We see de novo openings as essential to fueling future growth. During 2025, we launched nine new centers, a company record. As a reminder, our typical de novo ramps and hits breakeven in roughly one year, and our 2024 and 2025 center cohorts are performing exactly in line with those expectations. As we look forward, our intention is to launch between 8 and 10 de novos each year, and we don't have a preference regarding whether they're structured as wholly owned or joint ventures. February marked the opening of our first de novo this year, and right now we have strong visibility into hitting our 2026 target for new locations. We're eager to share additional information with you as the year progresses. For 2026, joint ventures are the next strategic priority we're concentrating on. A major point of differentiation comes from joint ventures, which bring health system objectives into alignment with how we pursue growth. More and more, health systems want ways to take part in the swift shift of care sites toward outpatient imaging, along with chances to expand their outpatient ambulatory presence. Our JV model offers an extremely effective way in. Because of the clinical, commercial and operational excellence we show, especially when developing de novos, Lumexa Imaging is positioned well to assist systems in carrying out these ambitions while staying dedicated to their wider enterprise priorities. In exchange, such partnerships speed up our footprint in whatever market we're in. We're building a strong pipeline of prospective partners, with numerous conversations underway at differing stages. One recent example I'd like to point to demonstrates how powerful our joint venture approach can be. During the latter half of last year, we formed a new partnership with the University of Pittsburgh Medical Center. Via this arrangement, we're collaborating with UPMC to support their aim of delivering access to imaging that is lower cost, high-quality and more convenient.
Simultaneously, our geographic presence is growing — Pennsylvania is being added, which brings us into 14 states. This partnership is still in its early days, yet site location planning is moving forward actively. Being selected by this health system — one that is forward-thinking and focused on results — has us energized. Regarding M&A tuck-ins, we keep assessing accretive opportunities and will stay highly disciplined in how we proceed. As the fourth quarter closed, we finished one small tuck-in acquisition — a new facility in North Carolina — which extends the strong partnership we have with Atrium. Another item on our 2026 strategic priority list is introducing new strategic service lines to boost acuity mix and gain efficiencies via innovation. Let me highlight a couple of items: mammography combined with cardiac screening — we call that breast arterial calcification — plus PET. At our mammography locations in South Jersey, we've just started offering breast arterial calcification, or BAC, screenings as a cash add-on assessment for cardiac health. Cardiovascular disease is one of the leading causes of death among women, and over 60 million women across the U.S. are living with some form of heart disease. A study published in the Journal of the American College of Cardiology found that BAC can act as a biomarker for assessing calcium buildup in the breast arteries, which may indicate heightened cardiovascular risk. Acceptance of this add-on has been strong since inception. Another key strategic priority for us is PET, which played a role in driving growth and a richer acuity mix during 2025. Through our Lumexa Alzheimer's Center of Excellence, we help pinpoint patients likely to benefit from newly emerging therapies for early-onset dementia by using amyloid PET scans. For those undergoing such treatment, as many as five MRI procedures are needed to watch for adverse effects. Enhancing access to PET is a meaningful way for us to support their journey of care. On a consolidated basis and system-wide alike, our PET volumes for the full year climbed at a mid-teens pace. Both BAC and PET contribute to our volume as well as our rate, and we are currently working to bring these strategic service lines into additional geographies. At this point, I'd like to spend a moment covering how we think about innovation. On the technology and AI front at Lumexa, our strategy centers on partnership rather than building everything ourselves. Going about it this way, in our view, speeds up how quickly we can put these tools to use, keeps our capital requirements lower, and gives us room to pick and choose among the strongest solutions as they hit the market. During Q4, we signed a deal with Ferrum Health, which is a top-tier AI convener. Think of Ferrum as an app store for AI in clinical imaging — it opens a single, integrated door for us to reach apps that already hold FDA clearance. Working with them lets us rapidly activate, assess, and track results from hundreds of AI applications, deploying them across different modalities and workflows, all while keeping our data and insights safeguarded. Best-in-class tools are being deployed everywhere in the organization. Colleagues who manage our shared back-office functions are part of this push as well, putting emerging agentic and generative AI tools to work so we can operate more efficiently. Wrapping up, I feel good about how Q4 turned out, and the wins we've racked up have our people fired up to hit our strategic goals during the next twelve months. We believe the big opportunity ahead of us is just starting to be tapped, and that Lumexa is set up nicely to deliver profitable growth throughout this year and afterward. Many thanks to our hardworking staff and to our radiologists. What we've accomplished stems directly from their hard work and commitment to giving our patients — who depend on us — the highest quality imaging experience. At this point I'll hand the call to Tony, who will walk through our fourth quarter in greater detail. Tony?
Thanks, Caitlin, and I appreciate everyone being on the call today as we go over our results. During this call, I'm going to walk through the financial results and talk about a few main factors behind how we performed this quarter. After that, I'll share what we expect for the full year 2026. To add color to my discussion of our GAAP financials on this call, I'll reference certain system-wide metrics so you can get a clearer picture of how the business is doing overall and how broad it is. System-wide metrics cover every center we run, which includes the 102 we own outright plus the 86 centers operated through our eight joint ventures with health systems. Because we hold a minority ownership position, the revenues and expenses of our health system JV centers don't show up in our GAAP revenues and expenses, yet they matter a great deal to how we perform, since we do capture our pro rata ownership portion of their net income and their cash flows within ours, and we also take in our pro rata portion of their EBITDA and our adjusted EBITDA. You can find the specifics of how our JVs performed financially in the quarterly disclosures accompanying our financial statements; we closed out 2025 with a robust Q4, one that showcased the growth formula we work toward over the long haul and our emphasis on advanced modalities, such as MRI, CT and PET. For the entire year, consolidated revenues reached $1.023 billion, up 7.8% from 2024. System-wide revenues rose 8.2% versus 2024. We additionally posted adjusted EBITDA of $230.2 million, a 14.6% gain over 2024, which works out to an adjusted EBITDA margin of 22.5%. Our cash flows came in strong and produced a reduction of more than half a turn in leverage ratio during a year when we launched a record 9 new centers, and leverage dropped another 2 turns to 3.5x levered in December thanks to our IPO and the debt refinancing tied to it. Now moving to our fourth quarter financials, beginning with revenues. Consolidated revenues for the fourth quarter totaled $267.7 million, which is 7.9% higher than the equivalent period a year ago. The biggest factor behind this growth was our return in network with a large payer in New Jersey. Beyond that, we saw procedure volumes rise at other locations and a continuing mix shift toward advanced imaging, which carries higher rates; we enjoyed robust system-wide performance at all our outpatient sites, whether wholly owned or within JVs. As our financial tables show, system-wide revenue growth for the quarter was 10.6%. Revenue per unit, covering both scan and read revenue, also gained from modest upticks in contracted rates with payers who value our lower price point relative to hospital-based services. Our outpatient revenues likewise increased as we ramped four sites added in 2024 along with the nine new sites we opened across 2025. In addition, our professional fee revenues, which make up our second operating segment, totaled $66.8 million, which reflects growth of 10.6%. Lastly, management fee and other revenues came to $57.2 million. These revenues are made up of two primary components. To start, every one of our health system JVs pays us a management fee for running the outpatient centers inside those JV structures. Next, we hire the staff at the centers and cover the cost of specific IT and other services ourselves on the JV sites' behalf, then effectively lease those back to the JV with no margin attached. That's what we refer to as pass-through revenues. You can find the pass-through revenue figure in a table that comes with our quarterly earnings release. Costs tied to refinancing our debt, plus other transaction expenses during our IPO year, produced a GAAP net loss of $28.7 million this quarter, versus a net loss of $25.1 million in last year's fourth quarter. Fourth quarter adjusted EBITDA came in at $63.8 million, up from $53.7 million in the prior-year period, which works out to an 18.6% increase. At 23.8%, our adjusted EBITDA margin was healthy, rising 150 basis points over last year's fourth quarter, which highlights how scalable our operating model is and how well we've executed on margin expansion initiatives. Let me remind everyone that adjusted EBITDA takes into account our pro rata ownership share of EBITDA across all our centers, whether wholly owned or held in health system JVs. A quick word on stock-based compensation. You can think of our stock-based comp as having two pieces. The first is the expense from shares issued as part of the purchase price for certain businesses acquired in 2020 and 2021. By the end of 2026, those costs will be fully amortized. The second piece is the expense from equity instruments granted to management and employees, and that's expected to remain a component of stock comp past 2026. Now on to the balance sheet; we closed the quarter with $58.8 million in cash and cash equivalents, versus $26.1 million at the close of 2024. Our balance sheet has been materially strengthened. As I mentioned earlier, we delevered by more than half a turn just through operating the business in 2025, even while opening a record nine de novos; after that, in December, we applied $406 million of net IPO proceeds toward paying down debt, cutting our leverage ratio by another 2 turns. Also in December, we earned improved credit ratings from S&P and Moody's, at B+ and B2 respectively, and we refinanced the term loan at a better interest rate. Thanks to this balance sheet strengthening activity, we anticipate annual cash savings exceeding $50 million. People sometimes raise questions about the debt held by our unconsolidated health system JVs; that figure will always be disclosed in our quarterly reporting; but here I'll point out that the year-end total stood at $69 million, mostly tied to financing equipment purchases at the centers. That amount doesn't appear on our balance sheet or factor into the leverage ratios we calculate for lenders. However, were we to factor in our pro rata ownership share of that debt, our leverage ratio would rise by only roughly 0.15x. We view our joint ventures as business models that use capital efficiently, help us meet our growth goals, and produce meaningful cash flow for both us and our health system partners. Strong cash flow keeps coming from our operations. Ahead of discussing guidance, let me restate the three priorities we have for allocating capital. First, we intend to finance growth of de novo facilities, upgrades to equipment, and investments into strategic service lines. Second, we might pursue strategic tuck-in acquisitions that are selected with care. Although those form part of our growth matrix, future M&A is not something our 2026 guidance relies upon. And third, looking further out, our goal is to bring our leverage profile down to under 3x. Because our business generates cash in a durable way, we think we're positioned well to carry out these three priorities. To phrase it differently, we think our business offers the flexibility to delever organically even as we completely fund our continuing capital needs and our growth strategy. Now let's turn to what we expect for the full year 2026. Same as what we pre-announced earlier this month, we still anticipate revenue falling within the range of $1.045 billion to $1.097 billion, and adjusted EBITDA falling within the range of $234 million to $242 million, which reflects roughly $7 million in public company costs that 2025 did not include.
If you look at the halfway point, adjusted EBITDA growth would come in at 7% once you set aside the costs tied to our first complete year running as a public company. We're also introducing guidance today for adjusted EPS, and our expectation sits in the range of $0.71 to $0.77 for each share. Volume growth should keep coming, with advanced modalities expanding at a quicker pace and accounting for a larger portion of the mix. That matters because advanced imaging generates more revenue for every procedure and better margins. Other modalities do affect our profits, though certain ones contribute more profit than others, and our marketing spending mirrors that reality; take X-ray, for instance, which made up 15% of system-wide volumes in 2025 yet contributed just 5% of revenues. Quarterly guidance isn't something we offer, but when I think about Q1, there's some extra context I'd like to pass along that could help shape expectations. Looking at seasonality, revenue and adjusted EBITDA tend to hit their low point during the first quarter. After that, results build as the year goes on, and the fourth quarter is reliably our best, since patients seek care before annual deductible resets kick in. Now that Q1 2026 is mostly in the rearview, we'd like to flag a few unusual timing factors. To start, we think part of our robust Q4 showing came from volumes that got pulled forward out of January and into December. Next, storms hit New Jersey, Texas and three additional Southern states during Q1, which put some pressure on volumes. We did manage to recapture part of those volumes before the quarter closed, yet we still expect these factors to leave Q1 adjusted EBITDA roughly level with Q1 of 2025. We think the rest of the lost volume can be recovered over the balance of 2026, and our confidence in the full year guidance hasn't wavered. Turning our attention to the longer term, consistent with what we discussed around our IPO, we see ourselves constructing a resilient growth engine powered by de novo expansion, growing sales at existing centers and broadening strategic service lines. Our growth initiatives are still in their earliest stages; and as new centers build up and the acuity mix changes alongside industry tailwinds that support our growth, we think we can reliably produce revenue growth at minimum on par with the market's. On top of that, the appealing economics of our units give us confidence that adjusted EBITDA can consistently climb at a faster clip than revenue. That closes out my look at our financials. 2025 brought exciting milestones and profitable growth, and we laid the groundwork for creating shareholder value over the long haul. Like Caitlin, I'm happy with how we performed this quarter, finishing the year from a position of strength. I'd also like to acknowledge that every bit of this depended on the dedication and effort of our team. Operator, please go ahead and open the line for questions.
So when we look ahead to 2026, how should we think about advanced imaging growth compared with routine? Will it resemble 2025? I know the Blue Cross tuck-in caused some distortion. And then, regarding the cadence of new center openings, how should we think about the quarterly rhythm as the year progresses?
Thanks so much, John. Yes. So we're staying focused on maintaining the expansion of our advanced imaging; we're extremely proud of the strength we demonstrated in the fourth quarter and across the year. As we mentioned in our prepared remarks, over the course of the year, advanced imaging rose 8% on a same-center basis, 7.1% on — pardon me, on a consolidated basis and 7.1% system-wide. We'll keep seeing that growth at a pace above our routine. When we consider routine, it's really made up of three separate modalities. There's your ultrasound, your mammography and your X-ray. X-ray, simply because of how fast and accessible it is, represents the largest end. It's the biggest number. It's the biggest piece. And clearly, we offer that for strategic reasons. But as Tony shared in his prepared remarks, it isn't tied to the overall performance of the business, and you observed that in Q4. So we'll keep concentrating on the strength of advanced and are excited to watch that continue expanding. And then to address your questions about de novos, delighted to say that we've already opened up this year, on track to deliver that 8 to 10. We have really good visibility when it comes to pacing, expect it to be weighted more toward the second half of the year with more of the openings, but we'll also have some additional openings in the first half.
Tony, could you provide some assistance regarding cash flow and CapEx for this year? After that, what portion of the CapEx do you anticipate will go toward equipment upgrades? Any perspective at all would be useful.
Absolutely, Whit. Indeed, like I mentioned during the prepared remarks and in the past, this is fortunately a business that generates substantial cash. We can pursue every one of our expansion plans while simultaneously reducing leverage annually. That truly positions us well, particularly following the IPO, lowering our debt and producing additional cash that can be utilized going forward to sort of sustain that deleveraging. Regarding how this has unfolded during 2025, our 10-K will be submitted no later than March 31, and it will contain further information about how — regarding what makes up the expenditure; however, we continue to stay very concentrated on the de novos as a massive portion of that outlay, putting money into the current locations for expansion; and then a maintenance element exists that represents sort of a small share of the spending, yet is required so that we keep having whatever we need at the sites we already operate.
Alright. So, circling back to this year's cash flow, I'm just attempting to map out how we get from '25 to '26. Could we take a simple approach — look at EBITDA growth, then add back the $50 million in interest savings — and arrive at a sensible figure? Or should we be factoring in some other moving pieces or items to consider?
Right now, cash flow guidance isn't something we're providing. So whatever I tell you on that front comes with that caveat, at least while we're still in this early stage as a newly public company. That said, at a high level, yes — the business is seeing the EBITDA growth you mentioned, plus substantial interest savings. Because we're carrying forward what we did in 2025 on growth CapEx and making sure the fleet is completely suited to our present requirements, 2026 is going to remain a year of heavy capital spending. As a result, our maintenance outlay has been somewhat higher than typical, and that will likely carry into 2026 as well. Still, the general direction of your thinking is correct.
Ben, on the rate side inside your 2026 guidance, what are you assuming for pricing in 2026? And what's your thinking on rate growth expectations across your main books for commercial, Medicare, and Medicaid payers this year? Thanks so much, Ben. Yes, Tony, maybe I'll have you say a bit about how we assume our growth algorithm.
Certainly. Certainly. When you look at how we expand across time, roughly two-thirds comes from volume while one-third comes from rate, and that roughly produces the same-site growth of about 7% that we see in outpatient. When you examine our consolidated financials, the revenue growth we report at the top line is slightly lower than that, since we have a second segment that is much smaller than outpatient and expands somewhat less, closer to 5%. We've discussed how that aligns with our broader strategy for growing that business. So the result is a blended growth rate nearer 6% — 5% to 6% at the top line. The outpatient business, though, is closer to 7%, with two-thirds from volume, largely through expansion in advanced modalities. The expansion in advanced — it accounts for roughly half of what we saw when it comes to rate increase, because those simply pay better, 3x to 4x better. So having more business there creates some rate growth; and then the remaining half of what we refer to as rate growth comes simply from escalators in contracted rates within the commercial book. And that's — we think we're actually being quite conservative about that right now.
I'd like to ask a bit more about cash flow and CapEx. Could you tell us what you anticipate total system-wide CapEx will be for 2026? And also explain how you expect that to move through the P&L and the cash flow statement, particularly for the nonconsolidated part?
Absolutely. Right now, we aren't providing a figure for what that will be in numerical terms. It does come through, I'd say, in several different ways on our cash flow statement. When it comes to our consolidated sites, to the extent we're using our own cash, it shows up in investing activities. We also have a supplemental disclosure covering CapEx that we finance simply by leasing those assets, which means no cash goes out. So when we file our 10-K, you'll be able to see that, in terms of what the 2025 numbers look like. What we spend on the health system JVs reduces the cash distribution we receive from them. That's a topic we'll address further once we've matured a bit more as a company. Our guidance metrics are staying fairly limited right now, but we'll be glad to share more on this down the road.
Andrew Mok asked whether, absent 2026 guidance, we could disclose the 2025 figure for capital expenditures across the entire system. J. Martin replied that he doubted it would appear as a distinct line in the 10-K, though he recalled that when we spoke with investors around the time of our IPO, our system-wide spending came to more than $100 million, and our proportional portion was far smaller, since on the amounts deployed within the health system joint ventures, we divide those costs proportionally alongside our health system partner.
This is Matthew Mardula, filling in for Ryan. So, during your prepared remarks, you brought this up when discussing Q4 results; however, given that most patients arrive through referring physicians, how is the team set up for this year to grow patient referrals into your imaging centers? Also, do you intend to launch additional initiatives or make changes aimed at strengthening and expanding physician relationships this year?
Yes, Matt, thank you very much. We do have a robust engagement approach when it comes to our referring physicians. More than 120 sales reps are embedded across our markets, and they interact with over 100,000 referring physicians. So engagement is extremely strong. When we look at it — our initial focus is on the specialties that refer the most: ortho, neuro, ENT, pain, urology, and gastro. In our prepared remarks, we called out a particular campaign focused on orthopedics during Q4, largely because that's their peak season too. And so orthopedics require imaging, and we were in a position to deliver that for them. We also run marketing initiatives, especially as we consider women who canceled mammograms amid the snow days in Q1. That means highly targeted outreach to ensure we're rescheduling and bringing our patients back onto the schedule for mammograms. So we'll keep up a high degree of engagement with referring physicians while ensuring we have focused messaging and strategies that address their needs.
I appreciate the details you gave us on the first quarter — that really helps. It would be useful to hear how you're framing the possible effect on volume, or perhaps on same-store revenue, coming from the weather as well as from those pull-forward dynamics. Then, when you look at the rest of the year beyond Q1, do you have a sense of how much of the volume you haven't yet recovered you're assuming you'll actually capture, versus what simply slips away and never materializes?
Yes. Thank you very much, Stephen. I'm grateful for that question. As we mentioned somewhat in the prepared remarks, and as we clearly witnessed at SCA and USPI, Q4 was consistently our strongest quarter when it comes to the deductible reset. So we're genuinely proud of what the team did to generate that strength in Q4. And clearly, we'll be doing the same thing again as we look ahead to 2026. When we consider the effect in Q1, it's roughly 50 to 50 — around 50% acceleration in Q4, and then roughly 50% of it tied to weather impact. The team is actively working on this. Of course, we know that any patients who had scans scheduled — our call center, our centralized call center, is contacting them to get them rescheduled. And beyond that, our sales team is working with referring physicians, who likewise had a backlog. So we're quite confident that we can keep driving volume growth. We're seeing strength after the storm, particularly in the advanced no growth. And with the mix of our strong sales efforts plus the operational strength of our team, we feel confident in the full year guidance.
Great. Yes, that's really useful. And then perhaps as well, if you could maybe give us your take on some of what's happening in the macro environment right now. Clearly, folks are paying attention when it comes to items such as the price of oil and the price of gas and stuff like that. I suppose, how are you approaching that? For instance, is there anything in your own P&L that we ought to keep in mind? And then when you consider the amount of money going toward capital, I guess, how are you weighing possible knock-on effects on the capital projects you may have?
Yes. Thank you very much, Stephen. We're paying close attention to everything happening in the broader economy and throughout our supply chain, and at this point we don't see any threat whatsoever to Lumexa Imaging. Some folks have asked us specifically about helium. To give you one illustration, helium has in fact been scarce for a number of years now, and we hold solid service agreements with our original equipment manufacturers that lock in equitable pricing for us. On top of that, we've lined up multiple secondary suppliers, and every one of them operates on fixed rates — the same holds true for gadolinium. For some added context, certain of the more recent MRs actually need a smaller amount of helium compared with earlier versions. The upgrades to our equipment that we've deliberately carried out across recent years give us added protection, so right now there's nothing you should be worrying about.
Jack Slevin here, filling in for Brian. Caitlin, I'd like to dig into some of the fascinating things you said regarding the FastScan launch and your other throughput programs. Could you expand a bit — I believe I heard the plan is that we reach 2/3 by the close of this year. But are there any initial signals regarding what that translates to on the efficiency side, or the kind of volume shift you've observed as it's been introduced across the initial half of the portfolio? Sure. Many thanks, Jack. I'm grateful for that question; we couldn't be more thrilled about FastScan. This is something we've spent years developing, and we were pleased to finish last year with FastScan on 50% of our MRI fleet. Put simply, FastScan cuts down how long an exam requires. For instance, an ankle MRI on a Siemens goes from 22 minutes to 8. Radiologists benefit since the picture comes out sharper. Patients benefit too, because their time inside the cramped MRI tube is reduced. And naturally, we benefit as well, since it frees up more scheduling room, usually around 40%. We stay quite disciplined with every dollar of capital we deploy, and with FastScan, the capability can be obtained either through buying a new machine or through a bolt-on software arrangement. That runs roughly $150,000. Clearly, that's a considerably lower price point. And we insist on being confident we can generate a robust IRR that clears our investment hurdles; so we require an approved business case prior to launch. So we're eager about the ongoing expansion, and it plays a major role in our confidence that we can deliver the insight growth for 2026 and afterward that we outlined in our growth algorithm.
I suppose if we look back at the first quarter, you had directed us toward EBITDA that was flat versus the prior year, yet the full-year outlook stayed unchanged. So at first, we were building models with quarterly guidance — roughly 6.7% EBITDA growth per quarter at the midpoint, leaving out that $7 million in public costs across each quarter of this year. But now Q1 comes in flat. So purely by the math, we ought to be modeling about 9% EBITDA growth each quarter from Q2 through Q4. What I'm wondering is — that looks like a pretty significant jump over the remaining year given a flat first quarter. What exactly is behind your confidence that EBITDA will rise 9% across the rest of the year?
Certainly. Pito, I appreciate that question. On a broad level, there's tremendous momentum in our business. We benefit from the strength of our advanced mods. We posted a record year for de novo openings in 2025, and those are ramping nicely. Last year's cadence leaned more toward the front half than the back half, and we already have one open in 2026. Beyond that, we have several JV discussions in progress at different stages. That reinforces our confidence in the wider demand for what we offer and how we operate. Then there's the tuck-in acquisition we told you about in December, plus we're assembling a pipeline of acquisition targets; and on top of all that, we have conviction and evidence supporting the growth of our strategic service lines, such as breast arterial calcification, with strong adoption in New Jersey and excellent clinical outcomes for our patients, above all else. So we'll be considering how to broaden that too. Tony, is there anything more you'd like to add regarding how we view the cadence across quarters?
Correct. Like we talked about, this is a business with seasonal patterns, and the way it climbs varies from one year to the next based on factors such as the weather and on how much behavior is driven by deductible resets. So that will shift, but each year we do build up quarter after quarter. Also, weather-related events and other interruptions at specific sites occur, whether that means referring physicians shutting for 2 days or our own locations shutting for 2 days. So we have a playbook we rely on to recover that volume. That's simply part of operating in this field. Every provider of health care services has such playbooks, and we definitely do, and we have used them. So at some point we do expect to bring back the remainder of that volume, and that strengthens how confident we are in our annual guidance.
Let me ask just two more things. How much did professional fee revenue come to in Q4, and what was it for the entire year?
In Q4, that figure stood at $66.8 million.
All right. Martin: As for the number for the entire year, I believe I included it in what I said earlier, though I definitely have it on hand.
Sure, I can get that for you. I mean, I can get that offline.
Right, and that’s definitely going to be included in our 10-K. We’ll be filing it no later than the 31st. But yes, we can definitely provide that.
And then, my other — and then, what did the professional fee come in at — for last year, the fourth quarter professional fee?
Yes. It — the growth rate came to 10.6% compared with the same period a year earlier; so that's how I'll address what you asked.
Does professional grew that much?
Yes.
All right, okay. Then moving to the second point — we've gone back and forth regarding the way to handle, sorry, the way to model management fee along with pass-through. In your disclosure, we'd assumed management fees amounted to 10% of revenue from your unconsolidated. So management fees appear to be greater than that, and likely that encompasses some items within your other revenue segments; but how should we approach managing — modeling management fees? Also, what margin does that business produce? Since I realize you don't break out the costs, just assist us in modeling that against the pass-through in 2026.
Yes. That's a good question. And I'm happy we can highlight the pass-throughs since that represents a large portion of revenues that doesn't truly drive anything from an EBITDA standpoint. So your question regarding what to focus on when it comes to modeling it makes a lot of sense to me. I believe what you've observed in the recent trend serves as the best indicator of the future on that. From a pure management fee standpoint, it is driven by a percentage of the revenues of the underlying JVs, and you can see the growth rates occurring at that level. There is — there's a bit of other revenue in that as well for some additional services we provide; so I think that combination isn't likely to change a whole lot regarding how it's growing and how you're looking at it.
So it should expand roughly at the same pace as consolidated revenue growth — or sorry, as system-wide revenue growth?
Broadly, that's the way we tend to view it, yes.
We appreciate the questions you've raised, and we're grateful for the ongoing interest you've shown in Lumexa Imaging. Throughout this call, you've heard that we're heading into 2026 with significant momentum, a well-defined strategy, and strong belief in our capacity to deliver. Our team stays dedicated to providing outstanding patient care, broadening reach for top-quality imaging, and pursuing growth that is both disciplined and profitable. Once more, I'd like to conclude by expressing gratitude to our committed team members and our radiologists. Their dedication to our mission, and to the patients and communities we serve, remains the cornerstone of everything we achieve. We value the time you've given us today and anticipate sharing updates on our progress in the coming quarters. Thank you.
This concludes today's conference. Thank you for your participation. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Lumexa Imaging Holdings, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Lumexa Imaging Holdings, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.